T-cell priming is strongly affected by the longevity of antigenbearing dendritic cells (DCs), which are typically short-lived in lymphoid tissues. 'Survival gene' Bcl-xl is critical for the lifespan of DCs in vivo. Here, we showed that in vivo coadministration of Bcl-xl under control of the DC-specific promoter (CD11c-Bcl-xl) and TRP2hsp70 DNA prolonged T-cell stimulation by DCs and augmented TRP2-specific-IFNg-producing CD8+ T-cell responses. Consistent with these findings, enhanced protection and significant therapeutic immunity to B16 melanoma was generated by this coimmunization strategy, which also augmented therapeutic immunity to GL-26 tumor. In this B16 melanoma model, results from animal experiments with depletion of immune cells indicate that CD8+ T cells and NK cells are important in the antitumor immunity induced by this coimmunization strategy. These observations suggest that 'survival gene' Bcl-xl potentiates the magnitude of antigen-specific-CD8+ T-cell responses and the efficacy of antitumor immunity induced by DNA vaccine, and is relevant for the design of in vivo targeted DC-based vaccine strategies to improve immunity against cancer. Gene Therapy (2005) 12, 1517-1525.
Introduction
Although various strategies have been tested to elicit an effective immune response to fight off tumor cells, there is no clear effective vaccine available.
1,2 DNA vaccination is potentially an efficient and conventional mean to induce antigen-specific adaptive and nonspecific innate immunity. 3 However, immune responses induced by DNA vaccines are usually too weak to be effective, as tumors continue to grow and metastasize in the body. 2, 3 Dendritic cells (DCs) bridge, initiate and regulate both innate and adaptive immunity, and play a central role in developing an effective tumor vaccine. 4 Recent investigations have been focused on modifying tumor antigens in order to target DCs for efficiently inducing immune responses in vivo. [5] [6] [7] Among molecules used to modify tumor antigens, heat shock protein 70 (hsp70) promotes DC activation and antigen presentation. 8, 9 Molecules such as murine b-defensin2, human IgG-Fc and aDEC-205 have been reported to target antigens to DCs. [5] [6] [7] Hsp70 may be another ideal molecule for fusion to tumor antigens for developing an effective tumor vaccine. Hsp70 has been fused to foreign antigens such as viral E7 or rat Her2/Neu to enhance the potency of DNA vaccines in murine tumor models. [10] [11] [12] Upon induction of maturation in vivo, DCs upregulate CCR7, a chemokine receptor that drives DCs to migrate to the lymphatics. 13 Once antigen-loaded DCs arrive at the local lymphatic organ, they process and present antigen to T cells. 4 In the T-cell area, antigen-bearing DCs are short-lived and may be killed by activated T cells. 14 The lifespan of activated antigen-bearing DCs has been estimated to be as short as 2-3 days. 15 The longevity of new migrant DCs in the lymphoid organs is most likely key in the induction of immunity. 16, 17 Thus, the efficacy of vaccines may be limited by the short-lived antigenbearing DCs in vivo. Prolonging DC survival promotes T-cell priming and would lead to the amplification of CD8+ T-cell immune responses. 14 Resistance of DCs to CTL lysis is likely to have a much greater impact on secondary immune responses. 14, 18 Recent findings provide direct evidence that the 'survival gene' Bcl-xl is required for the promotion of DC survival. 17, 19 Administration of Bcl-xl DNA that ubiquitously expresses 'antiapoptotic protein' Bcl-xl via gene-gun enhanced the efficiency of DNA vaccines. 20 However, several studies have demonstrated that induction of apoptosis could improve DNA vaccine potential. [21] [22] [23] It was proposed that dying antigen-expressing somatic cells would become attractive targets for infiltrating local DCs and presenting to CD8+ T cells through crosspriming. 24 It raises a possibility that delivery of Bcl-xl DNA into antigen-expressing somatic cells may limit antigen resources especially in crosspriming, which is critical in inducing antigen-specific CD8+ T-cell responses. Additionally, overexpression of Bcl-xl may contribute to tumorgensis in vivo. 25 This raises the concern that delivery of Bcl-xl DNA in vivo into somatic cells, B cells and stem cells may induce tumorgensis. Expressing Bclxl under control of the DC-specific (CD11c) promoter 26 would specifically prolong the lifespan of DCs without interfering with antigen-bearing somatic cells dying (an antigen resource for DCs), but at the same time may minimize the incidences of Bcl-xl-induced tumorgensis (due to the related short life, nonproliferation and terminal differentiation of DCs in vivo).
Tumor-associated antigens (TAA) are usually selfantigens and have poor immunogenicity. Testing tumor vaccine strategies in a self-antigen model may reflect more realistic antitumor immune response in humans. Naturally expressed tyrosinase-related protein 2 (TRP2) is a tissue differentiation antigen expressed by normal melanocytes, malignant melanocytes and glioblastoma. 27, 28 Murine B16 melanoma cells are weakly immunogenic and sublines exist with varying tumorigenic and metastatic capabilities, which are similar to human cancers. 29 Thus, TRP2 is an excellent self-antigen model to validate new tumor vaccine strategies against TRP2-expressing tumors such as B16 melanoma.
In the present work, we explored the ability to augment the magnitude of TRP2-specific CD8+ T-cell responses induced by TRP2hsp70 DNA via coadministrating CD11c-Bcl-xl DNA, and then tested the potentials of this immunization strategy to improve antitumor immunity in mouse self-antigen TRP2-expressing B16 melanoma and GL-26 glioma.
Results

TRP2hsp70 DNA vaccine induces protection but not therapeutic immunity to B16 melanoma
To test whether TRP2hsp70 DNA vaccine can induce effective antitumor immunity against B16 melanoma, C57BL/6 mice were vaccinated intramuscularly (i.m.) with TRP2hsp70, TRP2, hsp70 or pcDNA 3.1(+) DNA three times, weekly. After 2 weeks of last immunization, mice received s.c. 1 Â 10 5 viable B16 tumor cells. As shown in Figure 1a , TRP2hsp70 DNA vaccine induced significant protection antitumor activity in a B16 melanoma s.c. model. However, TRP2hsp70 DNA vaccine failed to elicit therapeutic antitumor activity in this model (Figure 1b ).
CD11c-Bcl-xl DNA vaccine prolongs T-cell stimulation by DCs and augments TRP2-specific-IFN-g-producing CD8+ T-cell responses
To determine whether CD11c-Bcl-xl DNA can prolong T-cell stimulation by DCs, mice were immunized i.m. by mixed TRP2hsp70 and CD11c-Bcl-xl, mixed TRP2hsp70 and CD11c-vector or mixed hsp70 and CD11c-Bcl-xl DNA on day 0. On day 2 or 12, DCs isolated freshly from pooled dLNs were cocultured with T cells isolated freshly from mice immunized by TRP2 DNA. DCs from mice immunized (2 days) by mixed TRP2hsp70 and CD11c-vector DNA significantly stimulated the production of IFN-g by T cells, whereas more IFN-g production occurred in DCs from mice immunized (2 days) by mixed TRP2hsp70 and CD11c-Bcl-xl DNA (Figure 2 ). DCs from mice immunized (12 days) by mixed TRP2hsp70 and CD11c-Bcl-xl DNA continually efficiently stimulated the production of IFN-g by T cells, whereas DCs from mice immunized (12 days) by mixed TRP2hsp70 and CD11c-vector DNA dramatically decreased the ability of stimulating T cells (Figure 2 ). DCs from mice immunized (2 or 12 days) by mixed hsp70 and CD11c-Bcl-xl DNA did not significantly stimulate the production of IFN-g by T cells (Figure 2 ). DCs or T cells alone did not produce significant IFN-g (Figure 2 ).
To test whether CD11c-Bcl-xl DNA can augment TRP2-specific-IFN-g-producing CD8+ T-cell responses induced by TRP2hsp70 DNA vaccine, mice were immunized i.m. by mixed TRP2hsp70 and CD11c-Bcl-xl, mixed TRP2hsp70 and CD11c-vector or mixed hsp70 and CD11c-Bcl-xl DNA three times, weekly. After 1 week or 7 weeks of last immunization, splenocytes from immunized mice were restimulated in vitro with TRP2 180À188 peptides. The TRP2-specific-IFN-g-producing CD8+ T-cell responses were detected by ELISPOT assay. As shown in Figure 3a , in vivo co-administration of TRP2hsp70 and CD11c-Bcl-xl DNA augmented TRP2-specific-IFN-g-producing CD8+ T-cell responses. The specificity of IFN-g-producing CD8+ T cells was confirmed by in vitro stimulation of splenocytes from mice immunized with mixed TRP2hsp70 and CD11c-Bcl-xl DNA using medium alone or the MHC class I matched irrelevant b-gal peptides (Figure 3b ). A week or 7 weeks after last immunization, fresh splenocytes (1 Â 10 6 / well/200 ml) including TRP2 180À188 peptides (1 mg/ml) or b-gal peptides (1 mg/ml) or medium alone were added to anti-mouse IFN-g mAbs precoated 96-well plates in RPMI1640 with 10%FBS at 371C with 7% CO 2 for 24 h and the ELISPOT plates were developed. TRP2hsp70/ CD11c-Bcl-xl versus TRP2hsp70/CD11c-vector (1 week): Po0.01, TRP2hsp70/CD11c-Bcl-xl versus TRP2hsp70/CD11c-vector (7 weeks): Po0.01. (b): the specificity of IFN-g-producing CD8+ T-cell responses. The experiments were performed as described above. TRP2 180À188 versus b-gal (1 week): Po0.01, TRP2 180À188 versus b-gal (7 weeks): Po0.05. The data are presented by combining two independent experiments.
Augmenting antitumor immunity by CD11c-Bcl-xl in vivo JH Kim et al were depleted by i.p. injection of anti-CD4, anti-CD8 or anti-NK antibodies. In this therapeutic setting, depletion of CD8+ T cells or NK cells decreased antitumor immunity, while depletion of CD4+ T cells slightly increased survival (Figure 4b ). To test the significant antitumor immunity induced by this coimmunization strategy in another tumor model, 5x10 5 viable GL-26 tumor (glioblastoma) cells, which express self-antigen TRP2, 28 were s.c. inoculated at the left flank on day 0. After 6 days, mice were immunized by mixed TRP2hsp70 and CD11c-Bcl-xl, mixed TRP2hsp70 and CD11c-vector or pcDNA3.1(+) DNA vaccine. As shown in Figure 5 , administration of mixed TRP2hsp70 and CD11c-Bcl-xl DNA augmented the efficacy of eradicating an established GL-26 tumor compared to mixed TRP2hsp70 and CD11c-vector DNA, while vector pcDNA 3.1(+) DNA failed to do so.
Discussion
Although murine TRP2 DNA vaccine was reported to induce protection anti-B16 immunity using C57BL/ 6 Â Balb/c F1 hybrid mice, 30 it failed to elicit antitumor Depletion of CD4+, CD8+ T cells or NK cells was performed by injection of the relevant antibodies on days À1, +1, +5, +12 and +19 (day of tumor challenge is referred to as day 0). TRP2hsp70/CD11c-Bcl-xl (n ¼ 10) versus TRP2hsp70/CD11c-vector (n ¼ 6): P-value o0.05; no depletion (n ¼ 10) versus CD8+ T cell (n ¼ 7) or NK (n ¼ 6) cell depletion: P-value o0.001; no depletion (n ¼ 10) versus CD4+ T (n ¼ 7) cell depletion: P-value 40.1. The data are presented by combining two independent experiments. (b) Therapeutic antitumor immunity induced by coadministration of TRP2hsp70 and CD11c-Bcl-xl DNA is independent on CD4+ T cells in B16 melanoma s.c. model. C57BL/6 mice were challenged s.c. with 1 Â 10 5 viable B16 tumor cells in 100 ml endotoxin-free 1 Â PBS at the left flank on day 0. Mice were vaccinated i.m. with mixed TRP2hsp70 and CD11c-Bcl-xl or mixed TRP2hsp70 and CD11c-vector (100 mg each DNA) on days 2, 4, 11, 18. Depletion of CD4+, CD8+ T cells or NK cells was performed by injection of the relevant antibodies on days À3, +1, +5, +12 and +19 (day of tumor challenge is referred to as day 0). TRP2hsp70/ CD11c-Bcl-xl (n ¼ 9) versus TRP2hsp70/CD11c-vector (n ¼ 6): P-value o0.05; No depletion (n ¼ 9) versus CD8+ (n ¼ 7) T-cell depletion: P-value o0.05; No depletion (n ¼ 9) versus CD4+ (n ¼ 7) T-cell depletion: P-value 40.2. The data are presented by combining two independent experiments. Augmenting antitumor immunity by CD11c-Bcl-xl in vivo JH Kim et al activity in syngeneic C57BL/6 mice ( Figure 1a and b, 31, 32 ). Foreign tumor antigens fused to hsp70 DNA vaccine have been shown to induce enhanced antitumor immunity in murine tumor models. [10] [11] [12] Murine selfantigen TRP2 fusion to hsp70 DNA vaccine significantly induced protection antitumor immunity, but failed to generate therapeutic antitumor activity (Figure 1a and b). These observations suggest that although TRP2hsp70 DNA vaccine can enhance antitumor immunity, improvement to this model is needed.
Various molecules (such as CpG-motifs, pro-inflammatory/Th1 cytokines, costimulatory/chemokines) or strategies (such as self-replicate, prime-boost strategies, targeting Ag to Ag presentation pathways, coadministration of an apoptosis gene together with the gene of Ag, induction of antiangiogenesis, various DNA delivery such as electroporation, intralymphatic injection) have been used to improve the potency of DNA vaccines. 33, 34 Targeting of DCs with GM-CSF and Flt3L DNA increased DC numbers in vivo and enhanced Ag-specific CD4+ T-cell responses. 35 The DNA vaccine was also designed to encode DC maturation signals. 36 Recently, synergistic recruitment, expansion and activation of DCs in vivo via coimmunization with MIP-1a, Flt3L and DNA encoding Ag has been reported to potentiate the immunogenicity of DNA vaccines. 34 It was suggested that the longevity of antigen-bearing DCs in lymphoid organs strongly affects T-cell priming in vivo.
14,17-19 The short lifespan of antigen-bearing DCs may be an obstacle in generating potent T-cell-mediated immune responses. It is particularly relevant in DNA immunization due to the low-transfection efficiency resulting in the very small numbers of antigen-bearing DCs in dLNs. 3 'Survival gene' Bcl-xl was reported to be critical in DC survival and in the magnitude of generated immune responses. 17, 19 Owing to the possibilities of apoptosis of antigen-bearing somatic cells presentation to CD8+ T cells by local DCs and Bcl-xl-induced tumorgensis, [21] [22] [23] 25 prolonging specifically DC survival in vivo may be an attractive strategy to improve T-cell responses.
Considering the in vivo antigen DNA delivery, accumulated evidence suggests that gene gun-mediated antigen delivery to the skin leads to Th2 immune responses. 37 However, i.m. DNA injection resulted in Th1-biased immune responses, 38 which favor antitumor immunity.
2-5 By using gene-gun delivery, Bcl-xl DNA that ubiquitously expresses 'antiapoptotic protein' Bcl-xl transfected skin DCs and prolonged DC survival. 20 In our studies, by using i.m. injection, Bcl-xl under control of the DC-specific promoter (CD11c-Bcl-xl) increased very little but significantly DC numbers and prolongs the lifespan of DCs in dLNs (unpublished observations). It is possible that delivering 'survival gene' Bcl-xl in vivo might promote DC migration to dLNs resulting in the increased DC numbers in dLNs. However, it is most likely that the increased numbers of DCs may result from the enhanced DC survival in dLNs. Although the tiny, almost undectectable population of GFP+ in CD11c+ DCs (o0.3% by FACS) was observed repeatedly in mice immunized i.m. with CD11c-EGFP DNA (unpublished observations), hard experimental evidence is lacking in the current work that indicates that DCs are directly transfected by CD11c-Bcl-xl DNA in vivo. However, genes under control of the DC-specific CD11c promoter have been demonstrated and generally accepted to specifically express in DCs in vivo. 16, 26 Our results indirectly indicates that DCs can be transfected by CD11c-Bcl-xl DNA (unpublished observations), and subsequently prolong T-cell stimulation in vivo ( Figure  2 ). Enhanced immunity by increased DC survival was reported in 'survival gene' Bcl-2 transgenic mice. 39 Coadministration of Bcl-xl and E7-based DNA vaccines via gene-gun generated enhanced E7-specific CD8+ T cell and memory response. 20, 40, 41 Our data show that augmented TRP2-specific-IFN-g-producing-CD8+ T-cell responses induced by mixed TRP2hsp70 DNA and CD11c-Bcl-xl DNA vaccine could last several weeks (Figure 3a) . The 'Ag' (TRP2hsp70) and 'survival' (Bcl-xl) genes are administered i.m. via two distinct constructs in this work, the chance of DCs being simultaneously transfected in vivo by both TRP2hsp70 and CD11c-Bcl-xl DNAs would be expected to be a rare event. However, it is entirely possible that some DCs transfected by only CD11c-Bcl-xl DNA may cross-present TRP2hsp70 derived epitopes produced by somatic cells or by alternate DCs that had become transfected by TRP2hsp70 DNA in vivo. This is not unexpected, as several studies have shown that very few Ag-presenting DCs are necessary to induce potent immune responses. 42, 43 It is likely that few 'prolonged' antigenbearing DCs can amplify Ag-specific T-cell responses (Figures 2 and 3 ) in this immunologic compartment. Taken together, these observations indicate that administration of CD11c-Bcl-xl DNA prolongs T-cell stimulation and improves the magnitude of TRP2-specific-CD8+ T-cell response induced by TRP2hsp70 DNA vaccine.
Coadministration of CD11c-Bcl-xl DNA not only augments protection antitumor immunity induced by TRP2hsp70 DNA vaccine (Figure 4a ), but also generates significant therapeutic antitumor activities (Figures 4b  and 5a ). Compared to mixed TRP2hsp70 and CD11c-Bcl-xl DNA vaccine, mixed TRP2hsp70 and CD11c-vector DNA did not induce significant antitumor immunity (Figures 4a, b and 5a, b) , implying the product of Bcl-xl but not the backbone of CD11c-vector enhances the efficacy of antitumor immunity. The role of CD4+ T cells in anti-B16 immunity has been debated in different studies using various immunization strategies. Some reports suggest that CD4+ T cells are critical in inducing effective anti-B16 immunity, 32,44-46 but others do not support this conclusion. 30, [47] [48] [49] In this prevention B16 model with mixed TRP2hsp70 and CD11c-Bcl-xl DNA vaccine, the efficacy of antitumor had no significant change but had an inhibitory effect in mice with CD4+ T-cell depletion (Figure 4a ). However, CD8+ T cells or NK cells were absolutely required for rejecting B16 tumor cells (Figure 4a ). These observations indicate that CD8+ T cells and NK cells are necessary for protection with B16 melanoma s.c. inoculation in this coimmunization strategy. In a therapeutic setting, depletion of CD8+ T cells or NK cells decreased the efficacy of anti-B16 immunity, while depletion of CD4+ T cells slightly enhanced the efficacy of anti-B16 immunity (Figure 4b ). It is possible that CD4+CD25+ regulatory T cells, which may suppress anti-B16 immunity, 49, 50 are also depleted by in vivo administration of anti-CD4 antibody in this model.
Survival curves alone are not sufficient and other parameters such as tumor size should be used to validate this approach. In our experimental system, there is no Augmenting antitumor immunity by CD11c-Bcl-xl in vivo JH Kim et al significant difference of tumor size between mice immunized with mixed TRP2hsp70 and CD11c-Bcl-xl DNA and control DNAs, death was frequently found in mice with a small tumor size (unpublished observations). To further evaluate the efficacy of antitumor immunity by this coimmunization strategy, we applied murine GL-26 tumor, which expresses TRP2 antigens. 28 In this model, vector pcDNA 3.1(+) could not eradicate an established GL-26 tumor (Figure 5c ). Compared to mixed TRP2hsp70 and CD11c-vector DNA vaccine, mixed TRP2hsp70 and CD11c-Bcl-xl DNA vaccine augmented the efficacy of eradicating an established GL-26 tumor (Figure 5a and b) . These observations indicate that coadministration of CD11c-Bcl-xl and tumor antigen DNA may be a generic mean to enhance the potency of DNA vaccination.
The difference in the levels of apoptotic DCs in LNs after CD11c-Bcl-xl DNA administration is significant but very little (unpublished observations). How such very small numbers of prolonged antigen-bearing DCs can activate and amplify antigen-specific CD8+ T-cell responses and subsequent antitumor immunity is unclear. It was suggested that DCs have extreme efficacy in stimulating T cells in the lymph lodes. 43 A recent study showed that individual long-lasting DC-T-cell interactions result in priming, whereas brief contact may contribute to the induction of T-cell tolerance. 51 It is likely that prolonged antigen-bearing DC survival may increase the chance or stability of DC-T-cell interactions during the induction of T-cell priming. Future studies need to be performed to determine whether: the transfection of DCs with Bcl-xl DNA change the level of expression of T-cell costimulatory molecules, MHC molecules, cytokines by the DCs or protect DCs from the Fas-mediated killing by freshly primed T cells; DC subsets are involved in T-cell priming; increased DC survival result in more DC-T-cell encounter, more prolonged DC-T-cell interactions, higher avidity of antigen-specific T cells, potent memory T-cell responses or improve chemokine-mediated T-cell trafficking in this self-antigen model. Finally, whether the presence of s.c. tumors alters DC survival in the LNs and the effect of CD11c-Bcl-xl DNA is highly interested to be investigated.
Regardless of the underlying precise mechanisms, delivering 'survival gene' Bcl-xl under control of the DCspecific (CD11c) promoter prolonged T-cell stimulation by DCs and enhanced TRP2-specific-IFN-g-CD8+ T-cell responses induced by TRP2hsp70 DNA vaccine. Immunity to B16 melanoma and GL-26 glioma induced by TRP2hsp70 DNA vaccine was significantly augmented by co-administration of CD11c-Bcl-xl DNA. These tumor models we have chosen in this study with true selfantigen, therefore having to overcome peripheral tolerance to the tumor antigens in order to generate an antitumor immune response, which has been very difficult to achieve with most vaccine approaches tested to date.
1,2 Hence, our observations may provide more direct information that coadministration of 'survival gene' Bcl-xl and 'antigen' TRP2hsp70 DNA vaccines might be a potential alternative way to optimize therapeutic immunity on the applicability in the clinic. However, a persistent DC stimulation of T cells may result in autoimmunity or T-cell anergy. Chronic infections have been shown to induce exhaustion or functional unresponsiveness in cytotoxic CD8+ T cells. A recent study showed that CD4+ T cells become ineffective if repeatedly stimulated. 52 These concerns need to be further investigated before testing this potential effective immunization strategy in the next generation of tumor vaccine clinical trials.
Materials and methods
Mice
Female 6-8-week-old C57BL/6 mice were purchased from Taconic or The Jackson Laboratory and maintained in a pathogen-free animal facility at the University of Pittsburgh. All animal procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
DNA constructs
The truncated mouse TRP2 (the transmembrane domain and the rest of C-terminal sequences and stop codon were deleted) 27 was cloned into pcDNA 3.1(+) expression vector (Invitrogen) at the unique sites of NheI and BamHI (pcDNA3.1(+)-TRP2-ns) using standard PCR clone strategy and primers: 5 0 CTAGCTAGCATGGGCC TTGTGGGATGGGGGCTT (P1) and 5 0 CGGGATCCTGA GAGAGTTGTGGACCAAACTGG. The human hsp70 53 was cloned into pcDNA3.1(+)-TRP2-ns vector at the unique sites of BamHI and NotI (TRP2hsp70) using standard PCR clone strategy and primers: 5 0 CGGGATC CATGGCCAAAGCCGCGGCAGTC and 5 0 ATAAGAAT GCGGCCGCCTAATCTACCTCCTCAATGGT (P2). TRP2 was generated by cloning truncated mouse TRP2 including stop codon into pcDNA 3.1(+) vector at the unique sites of NheI and BamHI using primers: P1 and 5 0 CGGG ATCCCTATGAGAGAGTTGTGGACCAAACTGG. Hsp70 was generated by cloning hsp70 including stop codon into pcDNA 3.1(+) vector at the unique sites of NheI and NotI using primers: 5' CTAGCTAGCATGGCCAAA GCCGCGGCAGTC and P2. Human antiapoptotic gene Bcl-xl 54 or EGFP was cloned into the CD11c-pDOI-5 vector 26 at the unique site of EcoR I using primers: Bcl-xl: 5 0 CGGAATTCACCATGTCTCAGAGCAACCGG and 5 0 CGGAATTCTCATTTCCGACTGAAGAG; EGFP: 5 0 CGG AATTCACCATGGTGAGCAAGGGCGAG and 5 0 CGGA ATTCTTACTTGTACAGCTCGTCCAT. All plasmids were confirmed by sequencing. Escherichia coli strain XL-1 blue (Stratagene) was transformed with TRP2hsp70, TRP2, hsp70, CD11c-Bcl-xl or CD11c-EGFP DNA and then grown in LB medium (Sigma). Large-scale preparation of the plasmids was performed using endotoxin-free plasmid-Giga purification kits (Qiagen). Purified DNA was suspended in endotoxin-free 1 Â PBS (Sigma) at the concentration of 1 mg/ml, and stored in aliquots at À201C for subsequent use.
Cell lines and peptides
The weakly immunogenic B16 cells (ATCC) are pigmented mouse melanoma cell line and syngeneic to C57BL/6 background mice. GL-26 cells 28 are mouse glioma cell line. Both B16 and GL-26 cell lines were maintained at 371C with 5% CO 2 in DMEM (IRVINE Scientific) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Hyclone), 2 mM glutamine (Life Technologies) and 1 Â antibiotic antimycotic solution (Sigma).
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The TRP2 180À188 peptide used in this study is a nine amino-acid sequence (SVYDFFVWL) derived from the TRP2 protein. 27 Control H-2K b -restricted peptide was b-galactosidase (b-gal) (DAPIYTNV). 44 Peptides (purity 495%) were synthesized and purified by HPLC in the core facility of University of Pittsburgh Cancer Institute. All peptides were dissolved in DMSO and diluted in 1 Â endotoxin-free PBS for final concentration.
DC survival assays
Age-matched C57BL/6 mice (4 per group) were immunized i.m. with CD11c-Bcl-xl or CD11c-vector DNA (100 mg). After 5 days, mice were killed and single-cell suspensions of pooled inguinal dLNs were prepared by collagenase D (Roche) digestion as described. 47 1 Â PBS with 0.5% FBS containing 2 mM EDTA was used to prevent reassociation of T cells with DCs during the isolation. dLNs cells were incubated for 20 min on ice with Fc block (anti-CD16/CD32, 1 mg/1x10 6 cells) (BD Pharmingen). CD11c+-DCs were purified using antiCD11c microbeads following the vendor instructions (Miltenyi). The purified CD11c+-DCs were counted and the numbers of CD11c+ cells were the mean of triplicates7s.e. in each group. The purified CD11c+ cells were washed once with cold 1 Â PBS. Cells 
CD8+ T-cell assays
C57BL/6 mice (two per group) were immunized i.m. with mixed TRP2hsp70 and CD11c-Bcl-xl, mixed TRP2hsp70 and CD11c-vector or mixed hsp70 and CD11c-Bcl-xl DNA (100 mg each DNA) three times, weekly. Mice were killed and single-cell suspensions were prepared 1 or 7 weeks after last immunization. Splenocytes (1 Â 10 6 /well/200ml) were cultured with TRP2 180À188 peptides (1 mg/ml) or b-gal peptides (1 mg/ ml) or medium alone in a 96-well plate, precoated with anti-mouse IFN-g mAbs at 371C with 7% CO 2 for 24 h (murine IFN-g ELISPOT kit from Biosource). Culture medium was RPMI1640 with 10%FBS. The ELISPOT plates were developed according to vendor instruction (Biosource). The spots were counted using a dissecting microscope. The spot numbers were the mean of triplicates7s.e. in each vaccinated group.
T-cell stimulation by DCs
To prepare DCs, C57BL/6 mice (three per group) were immunized i.m. by mixed TRP2hsp70 and CD11c-Bcl-xl, mixed TRP2hsp70 and CD11c-vector or mixed hsp70 and CD11c-Bcl-xl DNA (100 mg each DNA) on day 0. On day 2 or 12, DCs from pooled dLNs were isolated using anti-CD11c microbeads (Miltenyi). To prepare T cells, C57BL/6 mice (two per group) were immunized i.m. by TRP2 DNA (100 mg) three times, weekly. After 1 week of last immunization, T cells were isolated using mouse T-cell enrichment column (R&D system). DCs (1-10 Â 10 4 ) were then cocultured with T cells (2 Â 10 5 ) in 96-well plates precoated with anti-mouse IFN-g mAbs in RPMI1640 with 10%FBS at 371C with 7% CO 2 (murine IFN-g ELISPOT kit from Biosource) or 5% CO 2 (murine IFN-g ELISPOT kit from BD Pharmingen) for 24 h and the ELISPOT plates were developed as described in vendor instruction.
Depletion antibodies
Purified anti-CD4 (YTS 191.1.2 and YTA 3.1.2) and anti-CD8 (YTS 169.4.2.1 and YTS 156.7.7) antibodies were kindly provided by Dr H Waldmann. 55, 56 AntiasialoGM1 used to deplete NK cells was purchased from Wako Pharmaceuticals and dissolved in endotoxin-free 1 Â PBS.
Tumor models B16 tumor protection experiments. C57BL/6 mice were immunized i.m. with pcDNA 3.1(+), hsp70, TRP2, TRP2hsp70, mixed TRP2hsp70 and CD11c-vector or mixed TRP2hsp70 and CD11c-Bcl-xl DNA (100 mg each DNA) three times, weekly. Mice were injected s.c. with viable 1 Â 10 5 B16 tumor cells in 100 ml endotoxin-free 1 Â PBS at the left flank, 2 weeks after last vaccination. Depletion of CD4+, CD8+ T cells (200 mg i.p.) or NK cells (40 ml i.p.) was performed by injection of the relevant antibodies on days À1, +1, +5, +12 and +19 (day of tumor challenge is referred to as day 0).
B16 tumor therapeutic experiments. C57BL/6 mice were inoculated s.c. with 1 Â 10 5 viable B16 tumor cells in 100 ml endotoxin-free 1 Â PBS at the left flank on day 0. Mice were vaccinated i.m. with hsp70, TRP2, TRP2hsp70, mixed TRP2hsp70 and CD11c-vector or mixed TRP2hsp70 and CD11c-Bcl-xl DNA (100 mg each DNA) on days +2, +4, +11, +18. Depletion of CD4+, CD8+ T cells (200 mg i.p.) or NK cells (40 ml i.p.) was performed by injection of the relevant antibodies on days À3, +1, +5, +12 and + 19 (day of tumor challenge is referred to as day 0). Mice were carefully monitored and killed when: became sick from advanced tumors, ulceration occurred; tumor size reached 2 cm in mean diameter.
GL-26 tumor therapeutic experiments. C57BL/6 mice were inoculated s.c. with 5 Â 10 5 viable GL-26 tumor cells in 100 ml endotoxin-free 1 Â PBS at the left flank on day 0. On day 6, mice were immunized by pcDNA3.1(+), mixed TRP2hsp70 and CD11c-vector or mixed TRP2hsp70 and CD11c-Bcl-xl DNA vaccine (100 mg each DNA). Tumors were measured using an electric caliper in two perpendicular diameters every 2-3 days for 2 months.
Statistical analysis
Data were analyzed by one-way ANOVA with Bonferroni's multiple comparison test (GraphPad Prism version 4). P-values of o0.05 is considered significant. Animal survival is presented using Kaplan-Meier survival curves and was statistically analyzed using log rank test (GraphPad Prism version 4). Po0.05 is considered to be statistically significant.
